Merck Doubles Down on Biologics, Closing Plants and Cutting Jobs

  Merck & Co. filed with the U.S. Securities and Exchange Commission that it plans an extensive restructuring of its manufacturing and supply network. This will, it indicates, reduce its “global real estate footprint.” The restructuring is expected to be mostly completed by the end of 2023 and is projected to incur pre-tax costs between $800 million … Συνεχίστε να διαβάζετε Merck Doubles Down on Biologics, Closing Plants and Cutting Jobs.

Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI

Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI

Top 15 Best-Selling Drugs of 2018

Top 15 Best-Selling Drugs of 2018

Atara Biotherapeutics’ Cancer Drug Might—Might!—Have Applications for MS

Atara Biotherapeutics’ Cancer Drug Might—Might!—Have Applications for MS

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications

Top 10 Immuno-Oncology Startups

Top 10 Immuno-Oncology Startups

Top Clinical Trial Failures of 2018

Top Clinical Trial Failures of 2018